News

The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Prevent Blindness will offer downloadable fact sheets, shareable social media graphics and educational videos for patients

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

A specialist in the field of ophthalmology and gene therapy, Dr Girach’s appointment enhances SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development.

The company is announcing 3 market access partnerships with PhilRx, Apollo Care, and PARx Solutions, expanding US availability of the solution.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

DED incidence rates vary markedly depending on the ophthalmic practice.

Research can drive opportunities for patients with rare diseases

The company announced plans to enroll 320 volunteers in the study. Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Anchored matching-adjusted indirect comparison may aid decision-making

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care.

Catch up on Modern Retina's top stories, and ones you may have missed in 2023

A review of Opthalmology Times Europe's most important content from throughout the year

A look back at some of the biggest stories in 2023, from our US partners at Ophthalmology Times

Catch up on a few of Modern Retina's top stories and ones you may have missed in 2023

A review of Ophthalmology Times Europe's most important content from throughout the year.

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care

A tailored treatment plan can help surgeons offer personalized care for patients.

A look back at some of the biggest stories in ophthalmology in 2023.

Catch up on a few of our top stories and ones you may have missed in 2023

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

Jeff Todd, CEO and president of Prevent Blindness spoke with the Ophthalmology Times team about diabetes-related eye disease awareness at this year's American Academy of Ophthalmology meeting.